Jiangsu pharma firms eye first half for HK floats
Jiangsu Hansoh Pharmaceutical Co and Simcere Pharmaceutical Group are looking to raise a combined $2.5bn from Hong Kong IPOs that could launch in the first half of 2016.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: